MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?

Last week, Merck announced a definitive agreement to acquire Verona Pharma (VRNA) for approximately $10 billion. With this deal, Merck will add Verona's Ohtuvayre, approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Ohtuvayre was approved by the FDA in June last year, while regulatory filings in the EU are expected soon. The addition of Ohtuvayre is likely to strengthen Merck's cardio-pulmonary pipeline and portfolio as the drug's differentiated profile provides a signifi ...